ICU Medical, Inc. (NASDAQ:ICUI) will issue its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of $0.77 per share for the quarter. ICU Medical has set its FY17 guidance at $3.80-4.20 EPS.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.58 by ($0.06). ICU Medical had a return on equity of 7.56% and a net margin of 6.10%. The company had revenue of $331.51 million during the quarter, compared to the consensus estimate of $318.30 million. During the same period in the previous year, the company earned $1.15 earnings per share. ICU Medical’s quarterly revenue was up 242.8% on a year-over-year basis. On average, analysts expect ICU Medical to post $-4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

ICU Medical, Inc. (ICUI) opened at $190.90 on Monday. ICU Medical, Inc. has a one year low of $127.00 and a one year high of $195.20. The stock has a market cap of $3,813.80, a PE ratio of 52.59 and a beta of 0.33. The company has a quick ratio of 2.66, a current ratio of 4.78 and a debt-to-equity ratio of 0.07.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at

In other ICU Medical news, Director Robert S. Swinney sold 463 shares of the company’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $181.25, for a total value of $83,918.75. Following the sale, the director now owns 14,330 shares in the company, valued at $2,597,312.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Virginia Ruth Sanzone sold 1,784 shares of the company’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $174.47, for a total transaction of $311,254.48. Following the completion of the sale, the vice president now owns 102 shares in the company, valued at approximately $17,795.94. The disclosure for this sale can be found here. In the last 90 days, insiders sold 120,247 shares of company stock worth $22,708,888. Corporate insiders own 13.60% of the company’s stock.

ICUI has been the subject of a number of research reports. Zacks Investment Research raised shares of ICU Medical from a “sell” rating to a “hold” rating in a research note on Monday, September 11th. BidaskClub downgraded shares of ICU Medical from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. KeyCorp initiated coverage on shares of ICU Medical in a research note on Tuesday, October 17th. They issued a “sector weight” rating for the company. Finally, Gabelli reissued a “buy” rating on shares of ICU Medical in a research note on Friday, August 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. ICU Medical has an average rating of “Hold” and a consensus price target of $193.00.

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Earnings History for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.